Table VII.
Participation of lncRNAs in various diseases [based on (77, 103–110)].
| lncRNA | Disease | Function | (Refs.) |
|---|---|---|---|
| CRNDE-h | Colorectal cancer (CRC) | Promotes metabolic changes through insulin/IGF signaling | (103) |
| p21 | Prostate cancer (PCa) | Alter gene expression by modulating mRNA translation and suppressing the p53 or Wnt/β-catenin pathway | (104) |
| PCA3 | Prostate cancer (PCa) | Modulates the survival of cells downstream of androgen receptor signaling | (105) |
| BCAR4 | Breast cancer (BC) | Convert phenotype into an estrogen-independent, antiestrogen-resistant; tamoxifen resistance via HER2 signaling | (106) |
| ATB | Hepatocellular carcinoma (HCC) | Suppresses E-cadherin, leading to progression of epithelial tumor cells via inducing EMT | (107) |
| ANRIL | Non-small cell lung carcinoma (NSCLC) | Affects proliferation and apoptosis using suppression of KLF2 and P21 transcription | (108) |
| LINC00152 | Gastric cancer (GCA) | Connects with depth of invasion among gastric cancer patients | (109) |
| RP11-445H22.4 | Breast cancer (BC) | Its expression levels correlated with estrogen receptor (ER), progesterone receptor (PR), and menopausal status of the breast cancer patients; this molecule showed a remarkable improvement compared with CEA | (110) |
| RP11-1382.1 | Chronic kidney disease (CKD) | Unknown function | (77) |